CoChat
Sign Up
Cited by 88

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Overexpression of TFEB Drives a Pleiotropic Neurotrophic Effect and Prevents Parkinson’s Disease-Related Neurodegeneration

Torra, Albert, Parent, Annabelle, Cuadros, Thais, Rodríguez-Galván, Beatriz, Ruiz-Bronchal, Esther, Ballabio, Andrea, Bortolozzi, Analía, Vila, Miquel, Bové, Jordi·2018·Molecular Therapy
DOI 10.1016/j.ymthe.2018.02.022
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ymthe.2018.02.022

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 58

  1. Dehay, 2010, Pathogenic lysosomal depletion in Parkinson’s disease, J. Neurosci., 30, 12535, 10.1523/JNEUROSCI.1920-10.2010 · DOI · Paper page
  2. Bové, 2014, BAX channel activity mediates lysosomal disruption linked to Parkinson disease, Autophagy, 10, 889, 10.4161/auto.28286 · DOI · Paper page
  3. Chu, 2009, Alterations in lysosomal and proteasomal markers in Parkinson’s disease: relationship to alpha-synuclein inclusions, Neurobiol. Dis., 35, 385, 10.1016/j.nbd.2009.05.023 · DOI
  4. Sardiello, 2009, A gene network regulating lysosomal biogenesis and function, Science, 325, 473, 10.1126/science.1174447 · DOI · Paper page
  5. Palmieri, 2011, Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways, Hum. Mol. Genet., 20, 3852, 10.1093/hmg/ddr306 · DOI · Paper page
  6. Decressac, 2013, TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity, Proc. Natl. Acad. Sci. USA, 110, E1817, 10.1073/pnas.1305623110 · DOI · Paper page
  7. Haq, 2011, Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer, J. Clin. Oncol., 29, 3474, 10.1200/JCO.2010.32.6223 · DOI
  8. Kauffman, 2014, Molecular genetics and cellular characteristics of TFE3 and TFEB fusion kidney cancers, Nat. Rev. Urol., 11, 465, 10.1038/nrurol.2014.162 · DOI
  9. Hetman, 2004, Role of extracellular signal regulated kinases 1 and 2 in neuronal survival, Eur. J. Biochem., 271, 2050, 10.1111/j.1432-1033.2004.04133.x · DOI
  10. Kramer, 2015, GDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson disease, FEBS Lett., 589, 3760, 10.1016/j.febslet.2015.11.006 · DOI
  11. Napolitano, 2016, TFEB at a glance, J. Cell Sci., 129, 2475, 10.1242/jcs.146365 · DOI
  12. Polito, 2014, Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB, EMBO Mol. Med., 6, 1142, 10.15252/emmm.201303671 · DOI
  13. Grondin, 2002, Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys, Brain, 125, 2191, 10.1093/brain/awf234 · DOI
  14. Herzog, 2007, Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys, Mov. Disord., 22, 1124, 10.1002/mds.21503 · DOI
  15. Hyman, 1994, Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon, J. Neurosci., 14, 335, 10.1523/JNEUROSCI.14-01-00335.1994 · DOI
  16. Altar, 1992, Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo, Proc. Natl. Acad. Sci. USA, 89, 11347, 10.1073/pnas.89.23.11347 · DOI
  17. Fleckenstein, 2007, New insights into the mechanism of action of amphetamines, Annu. Rev. Pharmacol. Toxicol., 47, 681, 10.1146/annurev.pharmtox.47.120505.105140 · DOI · Paper page
  18. Fingar, 2002, Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E, Genes Dev., 16, 1472, 10.1101/gad.995802 · DOI · Paper page
  19. Schipany, 2015, eIF3 controls cell size independently of S6K1-activity, Oncotarget, 6, 24361, 10.18632/oncotarget.4458 · DOI
  20. Gingras, 1999, eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation, Annu. Rev. Biochem., 68, 913, 10.1146/annurev.biochem.68.1.913 · DOI
  21. Ruvinsky, 2006, Ribosomal protein S6 phosphorylation: from protein synthesis to cell size, Trends Biochem. Sci., 31, 342, 10.1016/j.tibs.2006.04.003 · DOI
  22. Di Malta, 2017, Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth, Science, 356, 1188, 10.1126/science.aag2553 · DOI
  23. Gomes, 2007, The VEGFR2 and PKA pathways converge at MEK/ERK1/2 to promote survival in serum deprived neuronal cells, Mol. Cell. Biochem., 305, 179, 10.1007/s11010-007-9542-2 · DOI
  24. Nicole, 2001, Neuroprotection mediated by glial cell line-derived neurotrophic factor: involvement of a reduction of NMDA-induced calcium influx by the mitogen-activated protein kinase pathway, J. Neurosci., 21, 3024, 10.1523/JNEUROSCI.21-09-03024.2001 · DOI
  25. Melillo, 2001, Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade, Mol. Cell. Biol., 21, 4177, 10.1128/MCB.21.13.4177-4187.2001 · DOI
  26. Frödin, 1999, Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction, Mol. Cell. Endocrinol., 151, 65, 10.1016/S0303-7207(99)00061-1 · DOI
  27. Besset, 2000, Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase, J. Biol. Chem., 275, 39159, 10.1074/jbc.M006908200 · DOI
  28. Hsuan, 2006, Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways, J. Neurosci., 26, 4481, 10.1523/JNEUROSCI.4922-05.2006 · DOI
  29. Robinet, 2010, Brain-derived neurotrophic factor enhances the expression of the monocarboxylate transporter 2 through translational activation in mouse cultured cortical neurons, J. Cereb. Blood Flow Metab., 30, 286, 10.1038/jcbfm.2009.208 · DOI
  30. Sarbassov, 2005, Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex, Science, 307, 1098, 10.1126/science.1106148 · DOI · Paper page
  31. Weiler, 2014, mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy, Proc. Natl. Acad. Sci. USA, 111, 409, 10.1073/pnas.1314469111 · DOI
  32. Ou, 2011, TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation, Mol. Cell, 41, 458, 10.1016/j.molcel.2011.01.019 · DOI
  33. Shu, 2014, Structural insights into the functions of TBK1 in innate antimicrobial immunity, Sctructure, 21, 1137, 10.1016/j.str.2013.04.025 · DOI
  34. Bové, 2012, Neurotoxin-based models of Parkinson’s disease, Neuroscience, 211, 51, 10.1016/j.neuroscience.2011.10.057 · DOI
  35. Jaeger, 1983, The effect of forebrain lesions in the neonatal rat: survival of midbrain dopaminergic neurons and the crossed nigrostriatal projection, J. Comp. Neurol., 218, 74, 10.1002/cne.902180105 · DOI
  36. Fox, 2016, Cross-hemispheric dopamine projections have functional significance, Proc. Natl. Acad. Sci. USA, 113, 6985, 10.1073/pnas.1603629113 · DOI
  37. Anglade, 1997, Apoptosis and autophagy in nigral neurons of patients with Parkinson’s disease, Histol. Histopathol., 12, 25
  38. Perier, 2012, Mitochondria and programmed cell death in Parkinson’s disease: apoptosis and beyond, Antioxid. Redox Signal., 16, 883, 10.1089/ars.2011.4074 · DOI
  39. Allan, 2009, Apoptosis and autophagy: regulation of caspase-9 by phosphorylation, FEBS J., 276, 6063, 10.1111/j.1742-4658.2009.07330.x · DOI
  40. Kim, 2011, Dissociation of progressive dopaminergic neuronal death and behavioral impairments by Bax deletion in a mouse model of Parkinson’s diseases, PLoS One, 6, e25346, 10.1371/journal.pone.0025346 · DOI
  41. Gingras, 1999, Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism, Genes Dev., 13, 1422, 10.1101/gad.13.11.1422 · DOI
  42. Cao, 2015, Light-regulated translational control of circadian behavior by eIF4E phosphorylation, Nat. Neurosci., 18, 855, 10.1038/nn.4010 · DOI
  43. Bushell, 2000, Cleavage of polypeptide chain initiation factor eIF4GI during apoptosis in lymphoma cells: characterisation of an internal fragment generated by caspase-3-mediated cleavage, Cell Death Differ., 7, 628, 10.1038/sj.cdd.4400699 · DOI
  44. Waskiewicz, 1999, Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo, Mol. Cell. Biol., 19, 1871, 10.1128/MCB.19.3.1871 · DOI
  45. Genheden, 2015, BDNF stimulation of protein synthesis in cortical neurons requires the MAP kinase-interacting kinase MNK1, J. Neurosci., 35, 972, 10.1523/JNEUROSCI.2641-14.2015 · DOI · Paper page
  46. Chauhan, 2013, ZKSCAN3 is a master transcriptional repressor of autophagy, Mol. Cell, 50, 16, 10.1016/j.molcel.2013.01.024 · DOI · Paper page
  47. Domanskyi, 2015, Prospects of neurotrophic factors for Parkinson’s disease: comparison of protein and gene therapy, Hum. Gene Ther., 26, 550, 10.1089/hum.2015.065 · DOI
  48. Olanow, 2015, Trophic factors for Parkinson’s disease: to live or let die, Mov. Disord., 30, 1715, 10.1002/mds.26426 · DOI
  49. Decressac, 2012, α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons, Sci. Transl. Med., 4, 163ra156, 10.1126/scitranslmed.3004676 · DOI
  50. Tomac, 1995, Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult, Proc. Natl. Acad. Sci. USA, 92, 8274, 10.1073/pnas.92.18.8274 · DOI
  51. Ries, 2006, Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson’s disease, Proc. Natl. Acad. Sci. USA, 103, 18757, 10.1073/pnas.0606401103 · DOI
  52. Lei, 2011, Signaling of glial cell line-derived neurotrophic factor and its receptor GFRα1 induce Nurr1 and Pitx3 to promote survival of grafted midbrain-derived neural stem cells in a rat model of Parkinson disease, J. Neuropathol. Exp. Neurol., 70, 736, 10.1097/NEN.0b013e31822830e5 · DOI
  53. Medina, 2011, Transcriptional activation of lysosomal exocytosis promotes cellular clearance, Dev. Cell, 21, 421, 10.1016/j.devcel.2011.07.016 · DOI
  54. Kordower, 2013, Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease, Brain, 136, 2419, 10.1093/brain/awt192 · DOI
  55. Zolotukhin, 1999, Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield, Gene Ther., 6, 973, 10.1038/sj.gt.3300938 · DOI
  56. Aurnhammer, 2012, Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences, Hum. Gene Ther. Methods, 23, 18, 10.1089/hgtb.2011.034 · DOI
  57. Bortolozzi, 2003, Control of 5-hydroxytryptamine release in the dorsal raphe nucleus by the noradrenergic system in rat brain. Role of alpha-adrenoceptors, Neuropsychopharmacology, 28, 421, 10.1038/sj.npp.1300061 · DOI
  58. Díaz-Mataix, 2005, Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action, J. Neurosci., 25, 10831, 10.1523/JNEUROSCI.2999-05.2005 · DOI

Cited by

Sorted by citations

Metadata

Authors
Torra, A., Parent, A., Cuadros, T., Rodríguez-Galván, B., Ruiz-Bronchal, E., Ballabio, A., Bortolozzi, A., Vila, M., & Bové, J.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2018-06
Volume
26
Issue
6
Pages
1552-1567
ISSN
1525-0016
DOI
10.1016/j.ymthe.2018.02.022
Cited by
88
References
4
Language
en
Licence
Funders
  • Instituto de Salud Carlos III (FI14/00613)
  • European Regional Development Fund

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review